Sunitinib malate as the salvage therapy in advanced rectal carcinoid tumor

Lu, Chun Chi; Lin, Hsuen Fu; Feng, Chun Che; Yu, Chih-Yung; Kao, Woei Yau

doi:10.1007/s00384-008-0521-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median time to tumor progression was 10.2 months in carcinoid patients with a one year survival of 83.4%. A more recent report demonstrated salvage activity of sunitinib against advanced rectal carcinoid [13]. Our index patient remains disease free on adjuvant sunitinib treatment at 31 months after nephrectomy despite node positive disease.…”

Section: Discussionmentioning

confidence: 74%

Immunohistochemical basis for adjuvant anti-angiogenic targeted therapy for renal carcinoid: Initial case report

Finley

Narula

Valera

et al. 2011

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Objectives To evaluate the immunohistochemical profile of a carcinoid (low grade neuroendocrine tumor of the kidney) from a patient with lymph node positive disease who remains disease free for 31 months after radical nephrectomy, lymph node dissection and adjuvant therapy with sunitinib malate. Methods Immunohistochemical staining was performed for chromogranin, synaptophysin, CD31, VEGF, HIF-1α, HIF-2, and Glut-1. Staining was evaluated in 3 high-power fields and samples scored as strongly positive (3+), moderately positive (2+), weakly positive (1+) or negative (0). A clear cell renal cell carcinoma was used as positive control. Results Immunohistochemical staining was strongly positive VEGF, weak to moderately positive for HIF-2 and negative for HIF-1α and Glut-1. Conclusions Our case of primary renal carcinoid stained intensely for VEGF and HIF-2 consistent with a VHL-HIF1-HIF2-Glut1 independent pathway for VEGF activation. These data suggest that like other neuroendocrine tumors, primary renal carcinoid is a potential target for anti-angiogenic therapy with sunitinib.

show abstract

Section: Discussionmentioning

confidence: 74%